Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
High adherence to the at-home, stool-based screening test is a positive sign, but its impact on survival outcomes is still unclear.
A new study finds that blood-based measures of TMB correlate with response to pembrolizumab-based therapy in advanced lung cancer.
Two studies characterize hematological recovery after CAR-T cell therapy.
Axi-cel and tisa-cel are prescribed to distinct patient populations, possibly due to differing CAR-T manufacturing times, and differences in resource utilization.
Recent studies suggest that some misunderstanding around lead-time bias continues to persist in the literature.
A recent study documents a downward trend in melanoma incidence in adolescents and young adults, but experts disagree about the causes.
Many individual metabolite changes are often common among cancers and not specific to RCC, making the identification of diagnostic or prognostic biomarkers difficult.
Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
